Actelion's Ponesimod Successful in Mid-Stage Trial in Patients With Moderate …
Actelion's ponesimod successful in mid-stage trial in patients with moderate …
Filed under: drug treatment news 2011
Jean-Paul Clozel, M.D. and Chief Executive Officer commented: "We are excited to now know that ponesimod, originating from Actelion's discovery effort, has the potential to become an important treatment option in immune-mediated disorders in addition …
Read more on Reuters
Exelixis Rebounds From 'Sell The News' Reaction
Filed under: drug treatment news 2011
Exelixis (NASDAQ: EXEL) is a biotech with a market capitalization of $ 896 million that recently received FDA approval on its flagship drug cabozantinib, which will be marketed under the name COMETRIQ for the treatment of Medullary Thyroid Cancer (MTC …
Read more on Seeking Alpha
Trends in Pharmaceutical Packaging
Filed under: drug treatment news 2011
During the 2013 edition of Pharmapack, this issue will be discussed during the conferences and workshops led by experts from drug manufacturing companies, health authorities and suppliers of anti-counterfeiting technologies. … The EU's falsified …
Read more on Packaging Europe
Why Novartis is Committing M to Cancer Research Trial? Hope, and Emily
Filed under: drug treatment news 2011
In August 2012, Novartis acquired exclusive rights from Penn to CART–19, the therapy now known as CTL019. Unlike trials for commercial development of drugs like Viagra or cholesterol meds where millions consume the same drugs, Emma's treatment …
Read more on brandchannel.com